Development of Radiomics Models to Predict Progression-Free Survival and Early Polymetastatic Progression in Patients With Lung Oligometastases Treated on the Single-Arm Phase II Stereotactic Ablative Radiotherapy-5 Trial
Abstract
Aims: Despite the increasing use of stereotactic ablative radiotherapy (SABR) for oligometastatic cancer, at present, accurate models to predict the time until disease progression are lacking. The study developed radiomics models to predict progression-free survival (PFS) and early polymetastatic progression (PMP) in order to improve upon basic clinical prognostic models in lung oligometastatic patients treated in the population-based single-arm SABR-5 trial.
Materials and methods: Among 134 patients treated for lung oligometastases in the SABR-5 trial, pretreatment computed tomography images were available for 126 patients for inclusion in this study. In total, 1116 radiomic features were extracted from the original, wavelet-filtered, and Laplacian of Gaussian (LoG)-filtered images using PyRadiomics. Analyses were developed to predict (1) PFS and (2) early PMP, defined as progression of more than 5 lesions within 6 months of SABR. Clinical-only (ECOG score, primary tumour type, oligoprogression, and gross tumour volume [GTV]), radiomics-only, and combined models were developed. Feature selection was performed using the Pearson correlation coefficient. Cox proportional hazards regression was used to predict PFS and stratify patients into high- and low-risk groups. For the early PMP model, a support vector machine was evaluated using 10-, 5-, and 3-fold cross-validation.
Results: The radiomics-only and combined models achieved a concordance index of 0.72 in the test set,…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 134 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.